-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Palbociclib in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Palbociclib in Cervical Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Palbociclib in Cervical Cancer Drug Details: Palbociclib (Ibrance, Agatha) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TORL-2307 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TORL-2307 in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TORL-2307 in Pancreatic Cancer Drug Details: TORL-2307 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TORL-2307 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TORL-2307 in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TORL-2307 in Gastric Cancer Drug Details: TORL-2307 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CNTY-101 in Primary Mediastinal B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CNTY-101 in Primary Mediastinal B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CNTY-101 in Primary Mediastinal B-Cell Lymphoma Drug Details: CNTY-101...
-
Product Insights
Cutaneous T-Cell Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Cutaneous T-Cell Lymphoma - Drugs In Development, 2023’, provides an overview of the Cutaneous T-Cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cutaneous T-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Mycosis Fungoides – Drugs In Development, 2023
Global Markets Direct’s, ‘Mycosis Fungoides - Drugs In Development, 2023’, provides an overview of the Mycosis Fungoides pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mycosis Fungoides, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Malaria – Drugs In Development, 2023
Global Markets Direct’s, ‘Malaria - Drugs In Development, 2023’, provides an overview of the Malaria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Malaria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CVGBM in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CVGBM in Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CVGBM in Glioblastoma Multiforme (GBM) Drug Details: The vaccine candidate is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Resminostat in Sezary Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Resminostat in Sezary Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Resminostat in Sezary Syndrome Drug Details: Resminostat (4SC-201, YHI-1001, BYK408740) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Resminostat in Mycosis Fungoides
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Resminostat in Mycosis Fungoides report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Resminostat in Mycosis Fungoides Drug Details: Resminostat (4SC-201, YHI-1001, BYK408740) is...